바이오소재 시장 규모, 점유율, 동향 분석 리포트 : 제품별, 용도별, 지역별, 부문 예측(2024-2030년)

Biomaterials Market Size, Share & Trends Analysis Report By Product (Natural, Metallic, Polymer), By Application (Cardiovascular, Orthopedics, Plastic Surgery), By Region, And Segment Forecasts, 2024 - 2030

US $ 5,950 ￦ 8,311,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,708,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,502,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

한글목차

바이오소재 시장 성장과 동향 :

Grand View Research, Inc.의 최신 리포트에 따르면 세계의 바이오소재 시장 규모는 2030년까지 4,887억 달러에 달하며, 예측 기간 중 CAGR은 15.6%를 기록할 것으로 예측됩니다.

생체재료의 응용은 생물의학 연구에서 급성장하고 있는 분야입니다. 최근 생체재료의 생물학적 활성, 적합성, 기계적 특성의 개선은 조직공학, 면역공학, 약물전달시스템에 응용할 수 있는 새로운 기회를 제공합니다.

고분자 생체재료의 생체적합성, 저독성, 재생성은 PEG 코팅 리포솜, 바이오폴리머 코팅 리포솜 등 표적 약물전달에 있으며, 강력한 약물전달제로서 시장 성장에 유리한 기회를 제공하고 있다, 나노 물질 약물전달과 같은 개선된 약물전달 접근법의 등장은 제약 및 의료 산업에서 바이오폴리머의 전망을 더욱 넓혀주고 있습니다.

생체 재료의 사용은 심폐 시스템 재생에 큰 도움이 되고 있습니다. 이러한 재료는 파종된 세포에 물리적 지지와 생리적, 화학적 단서를 제공하여 조직 재생 과정을 돕습니다. 생체 재료와 나노 기술 기술의 통합은 손상된 심근 세포의 세포 외 매트릭스의 재생을 자극하여 전통적인 장기 이식을 대체 할 수 있습니다.

바이오소재 시장 보고서 하이라이트

• 천연 및 합성 분해성 폴리머의 높은 가용성과 수술용 봉합사 및 임플란트로 광범위하게 사용되면서 폴리머 제품 부문의 매출 점유율이 가장 높았습니다.
• 천연물은 신약개발을 위한 신규 생리활성물질공급원으로 큰 인기를 얻으며 이 분야의 급격한 성장을 이끌었습니다.
• 만성 골격 및 근골격계 질환의 발생률이 증가함에 따라 정형외과용 생체재료에 대한 수요가 크게 증가할 것으로 예상됩니다.
• 코로나바이러스, 즉 SARS-COV-2에 의한 감염은 중합 효소 연쇄반응(PCR) 또는 비 PCR 방법을 기반으로 한 기존 생물 의학 장비를 사용하여 감지 할 수 있습니다.
• 피막 수축을 방지하기 위해 실리콘 유방 보형물의 표면 개질을 개선하는 것은 성형 수술 부문에서 가장 빠른 속도로 생체 재료의 사용을 촉진하는 요인 중 하나입니다.
• 바이오센서는 조직, 효소, 유기체 등 미생물이 생산하는 생체 분자나 생물학적 요소와 같은 분석물을 검출하는 데 사용되는 분석 장비입니다.
• 북미는 이벤트 개최 및 자금 지원 구상을 통해 바이오소재 사용을 촉진하는 공공 및 민간 기관의 존재로 인해 매출 점유율에서 시장을 독식할 것으로 예상됩니다.
• 아시아태평양은 주로 중국에서 저가의 바이오소재 제품을 개발하는 현지 제조업체가 다수 존재하기 때문에 급격한 성장이 예상됩니다.
• 이 시장에는 메드트로닉, 에보닉, DSM, BASF, 버클리 첨단 바이오매트리얼즈, 코발론 테크놀러지스, 진머 바이오메트 홀딩스 등 유수의 기업이 진출해 있습니다.
• 각 회사는 시장에서의 입지를 강화하기 위해 신제품 개발, 제휴, 지역 확장 등 여러 가지 전략적 성장 구상을 추진하고 있습니다.
• 예를 들어 2022년 3월 메드트로닉은 Vizient와의 협력을 발표하고 Vizient의 포트폴리오에 Touch Surgery Enterprise를 추가했습니다. 이 플랫폼은 AI 기반 비디오 관리 및 분석 플랫폼으로, 수술 팀에게 시술 기록 및 인사이트에 대한 손쉬운 액세스를 제공합니다.

목차

제1장 조사 방법과 범위

제2장 바이오소재 시장 : 주요 요약

• 시장 스냅숏
• 부문 스냅숏
• 경쟁 구도 스냅숏

제3장 바이오소재 시장 변수, 동향, 범위

• 시장 세분화와 범위
• 시장 계통 전망
  • 모시장 전망
  • 관련/보조 시장 전망
• 시장 역학
  • 시장 촉진요인 분석
  • 시장 억제요인 분석
• 바이오소재 시장 분석 툴
  • 업계 분석 - Porter의 산업 분석
  • PESTLE 분석

제4장 바이오소재 시장 : 제품 추정·동향 분석

• 부문 대시보드
• 세계의 바이오소재 시장 제품별 전망
• 2018-2030년 시장 규모와 예측 및 동향 분석
• 금속
• 천연
• 세라믹
• 폴리머

제5장 바이오소재 시장 : 용도 추정·동향 분석

• 부문 대시보드
• 세계의 바이오소재 시장의 용도별 전망
• 2018-2030년 시장 규모와 예측 및 동향 분석
• 심혈관
• 안과
• 정형외과
• 창상 치유
• 조직공학
• 미용성형
• 신경
• 기타

제6장 바이오소재 시장 : 지역 비즈니스 분석

• 지역 시장 대시보드
• 세계 지역 시장 스냅숏
• 시장 규모와 예측 동향 분석, 2018-2030년 :
• 북미
• 유럽
• 아시아태평양
• 라틴아메리카
• 중동 및 아프리카

제7장 바이오소재 시장 : 경쟁 구도

• 참여 기업
• 전략 매핑
• 기업 시장 현황 분석, 2023년
• 참여 기업의 개요
• Medtronic
• Evonik Industries AG
• Carpenter Technology Corporation
• Berkeley Advanced Biomaterials
• Invibio Ltd
• Zimmer Biomet Holdings, Inc
• BASF SE
• Covalon Technologies Ltd
• Stryker
• Johnson & Johnson
• Dentsply Sirona
• CoorsTek Inc
• Corbion
• Regenity Biosciences

KSA

영문 목차

영문목차

Biomaterials Market Growth & Trends:

The global biomaterials market size is expected to reach USD 488.70 billion by 2030, registering a CAGR of 15.6% over the forecast period, according to a new report by Grand View Research, Inc. The application of biomaterials represents a fast-growing field in biomedical research. Recent advances in the improvement of bioactivity, compatibility, and mechanical properties of biomaterials have introduced new opportunities for their application in tissue engineering, immune engineering, and drug delivery systems.

Biocompatibility, low toxicity, and renewable nature of polymeric biomaterials make them potent drug delivery agents in controlled and targeted drug delivery, thus providing lucrative opportunities for the market growth. The advent of improved drug delivery approaches, such as PEG-coated liposomes, biopolymer-coated liposomes, and nanomaterials drug delivery, further expands the prospects of these biopolymers in the pharmaceutical and medical industries.

Use of biomaterials has greatly benefited the regeneration of the cardiopulmonary system. These materials provide physical support and physiological and chemical cues to seeded cells to assist the tissue regeneration process. Integration of biomaterials with nanotechnology techniques also stimulates the regeneration of damaged cardiomyocytes' extracellular matrix, thus replacing the traditional organ transplantation procedures.

Biomaterials Market Report Highlights:

• High availability of natural and synthetic degradable polymers and their wide usage as surgical sutures and implants resulted in the largest revenue share of the polymers product segment
• Natural products have gained immense popularity as a source of novel bioactive substance for the development of novel drugs, leading to fastest growth of this segment
• Increasing incidence of chronic skeletal and musculoskeletal conditions is expected to raise the demand for biomaterials for orthopedics application at a large scale
• The infection from coronavirus, that is, SARS-COV-2 can be detected using existing biomedical devices which are based on either Polymerase Chain Reaction (PCR) or Non-PCR methods
• Improvement in the surface modification of silicone breast implants to prevent capsular contracture is one of the factors driving the biomaterial usage in the plastic surgery segment at the fastest rate
• Biosensor, is an analytical device that is used to detect analytes such as biomolecules or biological elements of species produced by micro-organisms, that is tissues, enzymes, and organelles
• North America is expected to dominate the market in terms of revenue share owing to the presence of public and private agencies promoting biomaterial usage by hosting events and funding initiatives
• Asia Pacific is anticipated to grow at a rapid pace owing to the presence of several local manufacturers developing low-cost biomaterial products, mainly in China
• Prominent players operating in the market include Medtronic, Evonik, DSM, BASF, Berkeley Advanced Biomaterials, Covalon Technologies, and Zimmer Biomet Holdings
• Companies are engaged in several strategic growth initiatives, such as novel product developments, partnerships, and regional expansion to reinforce their market presence
• For instance, in March 2022, Medtronic announced a collaboration with Vizient to add Touch Surgery Enterprise to Vizient's portfolio, which is an AI-powered video management and analytical platform that provides surgical teams with simple access to procedural recordings and insights

Table of Contents

Chapter 1. Methodology And Scope

• 1.1. Market Segmentation and Scope
  • 1.1.1. Segment Definitions
    • 1.1.1.1. Product Segment
    • 1.1.1.2. Application Segment
• 1.2. Regional Scope
• 1.3. Estimates And Forecast Timeline
• 1.4. Objectives
• 1.5. Research Methodology
• 1.6. Information Procurement
  • 1.6.1. Purchased Database
  • 1.6.2. GVR's Internal Database
  • 1.6.3. Secondary Sources
  • 1.6.4. Primary Research
• 1.7. Information Or Data Analysis
  • 1.7.1. Data Analysis Models
• 1.8. Market Formulation & Validation
• 1.9. Model Details
  • 1.9.1. Commodity Flow Analysis
• 1.10. List Of Primary Sources
• 1.11. List Of Abbreviations

Chapter 2. Biomaterials Market: Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshots
• 2.3. Competitive Landscape Snapshot

Chapter 3. Biomaterials Market Variables, Trends, & Scope

• 3.1. Market Segmentation and Scope
• 3.2. Market Lineage Outlook
  • 3.2.1. Parent Market Outlook
  • 3.2.2. Related/Ancillary Market Outlook
• 3.3. Market Dynamics
  • 3.3.1. Market Drivers Analysis
    • 3.3.1.1. Rising Demand As A Consequence Of Accidental Injuries & Chronic Conditions
    • 3.3.1.2. Advances In Biomaterials Technologies
    • 3.3.1.3. Expansion In The Usage Scope Of Biomaterials
  • 3.3.2. Market Restraint Analysis
    • 3.3.2.1. High Expense Associated With The Development Of Biomaterials
    • 3.3.2.2. Problems Related To Biocompatibility Of Biomaterials
• 3.4. Biomaterials Market Analysis Tools
  • 3.4.1. Industry Analysis - Porter's
  • 3.4.2. PESTLE Analysis

Chapter 4. Biomaterials Market: Product Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Global Biomaterials Market By Product Outlook
• 4.3. Market Size & Forecasts And Trend Analyses, 2018 To 2030 For The Following
  • 4.3.1. Metallic
    • 4.3.1.1. Market Estimates And Forecasts 2018 To 2030 (USD Million)
  • 4.3.2. Natural
    • 4.3.2.1. Market Estimates And Forecasts 2018 To 2030 (USD Million)
  • 4.3.3. Ceramics
    • 4.3.3.1. Market Estimates And Forecasts 2018 To 2030 (USD Million)
  • 4.3.4. Polymers
    • 4.3.4.1. Market Estimates And Forecasts 2018 To 2030 (USD Million)

Chapter 5. Biomaterials Market: Application Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Global Biomaterials Market By Application Outlook
• 5.3. Market Size & Forecasts And Trend Analyses, 2018 To 2030 For The Following
  • 5.3.1. Cardiovascular
    • 5.3.1.1. Market Estimates And Forecasts 2018 To 2030 (USD Million)
    • 5.3.1.2. Sensors
    • 5.3.1.2.1. Market Estimates And Forecasts 2018 To 2030 (USD Million)
    • 5.3.1.3. Stents
    • 5.3.1.3.1. Market Estimates And Forecasts 2018 To 2030 (USD Million)
    • 5.3.1.4. Guidewires
    • 5.3.1.4.1. Market Estimates And Forecasts 2018 To 2030 (USD Million)
    • 5.3.1.5. Implantable Cardiac Defibrillators
    • 5.3.1.5.1. Market Estimates And Forecasts 2018 To 2030 (USD Million)
    • 5.3.1.6. Pacemakers
    • 5.3.1.6.1. Market Estimates And Forecasts 2018 To 2030 (USD Million)
    • 5.3.1.7. Vascular Grafts
    • 5.3.1.7.1. Market Estimates And Forecasts 2018 To 2030 (USD Million)
    • 5.3.1.8. Others
    • 5.3.1.8.1. Market Estimates And Forecasts 2018 To 2030 (USD Million)
  • 5.3.2. Ophthalmology
    • 5.3.2.1. Market Estimates And Forecasts 2018 To 2030 (USD Million)
    • 5.3.2.2. Synthetic Corneas
    • 5.3.2.2.1. Market Estimates And Forecasts 2018 To 2030 (USD Million)
    • 5.3.2.3. Intraocular Lens
    • 5.3.2.3.1. Market Estimates And Forecasts 2018 To 2030 (USD Million)
    • 5.3.2.4. Contact Lens
    • 5.3.2.4.1. Market Estimates And Forecasts 2018 To 2030 (USD Million)
    • 5.3.2.5. Ocular Tissue Replacement
    • 5.3.2.5.1. Market Estimates And Forecasts 2018 To 2030 (USD Million)
    • 5.3.2.6. Others
    • 5.3.2.6.1. Market Estimates And Forecasts 2018 To 2030 (USD Million)
  • 5.3.3. Dental
    • 5.3.3.1. Market Estimates And Forecasts 2018 To 2030 (USD Million)
    • 5.3.3.2. Tissue Regeneration Materials
    • 5.3.3.2.1. Market Estimates And Forecasts 2018 To 2030 (USD Million)
    • 5.3.3.3. Dental Implants
    • 5.3.3.3.1. Market Estimates And Forecasts 2018 To 2030 (USD Million)
    • 5.3.3.4. Bone Grafts & Substitutes
    • 5.3.3.4.1. Market Estimates And Forecasts 2018 To 2030 (USD Million)
    • 5.3.3.5. Dental Membranes
    • 5.3.3.5.1. Market Estimates And Forecasts 2018 To 2030 (USD Million)
    • 5.3.3.6. Others
    • 5.3.3.6.1. Market Estimates And Forecasts 2018 To 2030 (USD Million)
  • 5.3.4. Orthopedic
    • 5.3.4.1. Market Estimates And Forecasts 2018 To 2030 (USD Million)
    • 5.3.4.2. Joint Replacement biomaterials
    • 5.3.4.2.1. Market Estimates And Forecasts 2018 To 2030 (USD Million)
    • 5.3.4.3. Orthobiologics
    • 5.3.4.3.1. Market Estimates And Forecasts 2018 To 2030 (USD Million)
    • 5.3.4.4. Bioresorbable Tissue Fixation Products
    • 5.3.4.4.1. Market Estimates And Forecasts 2018 To 2030 (USD Million)
    • 5.3.4.5. Visco supplementation
    • 5.3.4.5.1. Market Estimates And Forecasts 2018 To 2030 (USD Million)
    • 5.3.4.6. Spine Biomaterial
    • 5.3.4.6.1. Market Estimates And Forecasts 2018 To 2030 (USD Million)
    • 5.3.4.7. Others
    • 5.3.4.7.1. Market Estimates And Forecasts 2018 To 2030 (USD Million)
  • 5.3.5. Wound Healing
    • 5.3.5.1. Market Estimates And Forecasts 2018 To 2030 (USD Million)
    • 5.3.5.2. Fracture Healing Device
    • 5.3.5.2.1. Market Estimates And Forecasts 2018 To 2030 (USD Million)
    • 5.3.5.3. Adhesion Barrier
    • 5.3.5.3.1. Market Estimates And Forecasts 2018 To 2030 (USD Million)
    • 5.3.5.4. Skin Substitutes
    • 5.3.5.4.1. Market Estimates And Forecasts 2018 To 2030 (USD Million)
    • 5.3.5.5. Internal Tissue Sealant
    • 5.3.5.5.1. Market Estimates And Forecasts 2018 To 2030 (USD Million)
    • 5.3.5.6. Surgical Hemostats
    • 5.3.5.6.1. Market Estimates And Forecasts 2018 To 2030 (USD Million)
    • 5.3.5.7. Others
    • 5.3.5.7.1. Market Estimates And Forecasts 2018 To 2030 (USD Million)
  • 5.3.6. Tissue Engineering
    • 5.3.6.1. Market Estimates And Forecasts 2018 To 2030 (USD Million)
  • 5.3.7. Plastic Surgery
    • 5.3.7.1. Market Estimates And Forecasts 2018 To 2030 (USD Million)
    • 5.3.7.2. Facial Wrinkle Treatment
    • 5.3.7.2.1. Market Estimates And Forecasts 2018 To 2030 (USD Million)
    • 5.3.7.3. Soft Tissue Fillers
    • 5.3.7.3.1. Market Estimates And Forecasts 2018 To 2030 (USD Million)
    • 5.3.7.4. Craniofacial Surgery
    • 5.3.7.4.1. Market Estimates And Forecasts 2018 To 2030 (USD Million)
    • 5.3.7.5. Bioengineered Skins
    • 5.3.7.5.1. Market Estimates And Forecasts 2018 To 2030 (USD Million)
    • 5.3.7.6. Peripheral Nerve Repair
    • 5.3.7.6.1. Market Estimates And Forecasts 2018 To 2030 (USD Million)
    • 5.3.7.7. Acellular Dermal Matrices
    • 5.3.7.7.1. Market Estimates And Forecasts 2018 To 2030 (USD Million)
    • 5.3.7.8. Others
    • 5.3.7.8.1. Market Estimates And Forecasts 2018 To 2030 (USD Million)
  • 5.3.8. Neurology
    • 5.3.8.1. Market Estimates And Forecasts 2018 To 2030 (USD Million)
    • 5.3.8.2. Neural Stem Cell Encapsulation
    • 5.3.8.2.1. Market Estimates And Forecasts 2018 To 2030 (USD Million)
    • 5.3.8.3. Shunting Systems
    • 5.3.8.3.1. Market Estimates And Forecasts 2018 To 2030 (USD Million)
    • 5.3.8.4. Hydrogel Scaffold For CNS Repair
    • 5.3.8.4.1. Market Estimates And Forecasts 2018 To 2030 (USD Million)
    • 5.3.8.5. Cortical Neural Prosthetics
    • 5.3.8.5.1. Market Estimates And Forecasts 2018 To 2030 (USD Million)
    • 5.3.8.6. Others
    • 5.3.8.6.1. Market Estimates And Forecasts 2018 To 2030 (USD Million)
  • 5.3.9. Others
    • 5.3.9.1. Market Estimates And Forecasts 2018 To 2030 (USD Million)

Chapter 6. Biomaterials Market: Regional Business Analysis

• 6.1. Regional Market Dashboard
• 6.2. Global Regional Market Snapshot
• 6.3. Marker Size, & Forecasts Trend Analysis, 2018 To 2030:
• 6.4. North America
  • 6.4.1. North America Market Estimates And Forecasts 2018 To 2030 (USD Million)
  • 6.4.2. U.S.
    • 6.4.2.1. Key Country Dynamics
    • 6.4.2.2. Competitive Scenario
    • 6.4.2.3. Regulatory Framework
    • 6.4.2.4. U.S. Market Estimates And Forecasts 2018 To 2030 (USD Million)
  • 6.4.3. Canada
    • 6.4.3.1. Key Country Dynamics
    • 6.4.3.2. Competitive Scenario
    • 6.4.3.3. Regulatory Framework
    • 6.4.3.4. Canada Market Estimates And Forecasts 2018 To 2030 (USD Million)
• 6.5. Europe
  • 6.5.1. Europe Market Estimates And Forecasts 2018 To 2030 (USD Million)
  • 6.5.2. UK
    • 6.5.2.1. Key Country Dynamics
    • 6.5.2.2. Competitive Scenario
    • 6.5.2.3. Regulatory Framework
    • 6.5.2.4. UK Market Estimates And Forecasts 2018 To 2030 (USD Million)
  • 6.5.3. Germany
    • 6.5.3.1. Key Country Dynamics
    • 6.5.3.2. Competitive Scenario
    • 6.5.3.3. Regulatory Framework
    • 6.5.3.4. Germany Market Estimates And Forecasts 2018 To 2030 (USD Million)
  • 6.5.4. Spain
    • 6.5.4.1. Key Country Dynamics
    • 6.5.4.2. Competitive Scenario
    • 6.5.4.3. Regulatory Framework
    • 6.5.4.4. Spain Market Estimates And Forecasts 2018 To 2030 (USD Million)
  • 6.5.5. France
    • 6.5.5.1. Key Country Dynamics
    • 6.5.5.2. Competitive Scenario
    • 6.5.5.3. Regulatory Framework
    • 6.5.5.4. France Market Estimates And Forecasts 2018 To 2030 (USD Million)
  • 6.5.6. Italy
    • 6.5.6.1. Key Country Dynamics
    • 6.5.6.2. Competitive Scenario
    • 6.5.6.3. Regulatory Framework
    • 6.5.6.4. Italy Market Estimates And Forecasts 2018 To 2030 (USD Million)
  • 6.5.7. Denmark
    • 6.5.7.1. Key Country Dynamics
    • 6.5.7.2. Competitive Scenario
    • 6.5.7.3. Regulatory Framework
    • 6.5.7.4. Denmark Market Estimates And Forecasts 2018 To 2030 (USD Million)
  • 6.5.8. Sweden
    • 6.5.8.1. Key Country Dynamics
    • 6.5.8.2. Competitive Scenario
    • 6.5.8.3. Regulatory Framework
    • 6.5.8.4. Sweden Market Estimates And Forecasts 2018 To 2030 (USD Million)
  • 6.5.9. Norway
    • 6.5.9.1. Key Country Dynamics
    • 6.5.9.2. Competitive Scenario
    • 6.5.9.3. Regulatory Framework
    • 6.5.9.4. Norway Market Estimates And Forecasts 2018 To 2030 (USD Million)
• 6.6. Asia Pacific
  • 6.6.1. Asia Pacific Market Estimates And Forecasts 2018 To 2030 (USD Million)
  • 6.6.2. Japan
    • 6.6.2.1. Key Country Dynamics
    • 6.6.2.2. Competitive Scenario
    • 6.6.2.3. Regulatory Framework
    • 6.6.2.4. Japan Market Estimates And Forecasts 2018 To 2030 (USD Million)
  • 6.6.3. China
    • 6.6.3.1. Key Country Dynamics
    • 6.6.3.2. Competitive Scenario
    • 6.6.3.3. Regulatory Framework
    • 6.6.3.4. China Market Estimates And Forecasts 2018 To 2030 (USD Million)
  • 6.6.4. India
    • 6.6.4.1. Key Country Dynamics
    • 6.6.4.2. Competitive Scenario
    • 6.6.4.3. Regulatory Framework
    • 6.6.4.4. India Market Estimates And Forecasts 2018 To 2030 (USD Million)
  • 6.6.5. South Korea
    • 6.6.5.1. Key Country Dynamics
    • 6.6.5.2. Competitive Scenario
    • 6.6.5.3. Regulatory Framework
    • 6.6.5.4. South Korea Market Estimates And Forecasts 2018 To 2030 (USD Million)
  • 6.6.6. Thailand
    • 6.6.6.1. Key Country Dynamics
    • 6.6.6.2. Competitive Scenario
    • 6.6.6.3. Regulatory Framework
    • 6.6.6.4. Thailand Market Estimates And Forecasts 2018 To 2030 (USD Million)
  • 6.6.7. Australia
    • 6.6.7.1. Key Country Dynamics
    • 6.6.7.2. Competitive Scenario
    • 6.6.7.3. Regulatory Framework
    • 6.6.7.4. Australia Market Estimates And Forecasts 2018 To 2030 (USD Million)
• 6.7. Latin America
  • 6.7.1. Latin America Market Estimates And Forecasts 2018 To 2030 (USD Million)
  • 6.7.2. Brazil
    • 6.7.2.1. Key Country Dynamics
    • 6.7.2.2. Competitive Scenario
    • 6.7.2.3. Regulatory Framework
    • 6.7.2.4. Brazil Market Estimates And Forecasts 2018 To 2030 (USD Million)
  • 6.7.3. Mexico
    • 6.7.3.1. Key Country Dynamics
    • 6.7.3.2. Competitive Scenario
    • 6.7.3.3. Regulatory Framework
    • 6.7.3.4. Mexico Biomaterials Market, 2018 - 2030 (USD Million)
  • 6.7.4. Argentina
    • 6.7.4.1. Key Country Dynamics
    • 6.7.4.2. Competitive Scenario
    • 6.7.4.3. Regulatory Framework
    • 6.7.4.4. Argentina Market Estimates And Forecasts 2018 To 2030 (USD Million)
• 6.8. MEA
  • 6.8.1. MEA Biomaterials Market, 2018 - 2030 (USD Million)
  • 6.8.2. South Africa
    • 6.8.2.1. Key Country Dynamics
    • 6.8.2.2. Competitive Scenario
    • 6.8.2.3. Regulatory Framework
    • 6.8.2.4. South Africa Market Estimates And Forecasts 2018 To 2030 (USD Million)
  • 6.8.3. Saudi Arabia
    • 6.8.3.1. Key Country Dynamics
    • 6.8.3.2. Competitive Scenario
    • 6.8.3.3. Regulatory Framework
    • 6.8.3.4. Saudi Arabia Market Estimates And Forecasts 2018 To 2030 (USD Million)
  • 6.8.4. UAE
    • 6.8.4.1. Key Country Dynamics
    • 6.8.4.2. Competitive Scenario
    • 6.8.4.3. Regulatory Framework
    • 6.8.4.4. UAE Market Estimates And Forecasts 2018 To 2030 (USD Million)
  • 6.8.5. Kuwait
    • 6.8.5.1. Key Country Dynamics
    • 6.8.5.2. Competitive Scenario
    • 6.8.5.3. Regulatory Framework
    • 6.8.5.4. Kuwait Market Estimates And Forecasts 2018 To 2030 (USD Million)

Chapter 7. Biomaterials Market: Competitive Landscape

• 7.1. Participant Categorization
• 7.2. Strategy Mapping
• 7.3. Company Market Position Analysis, 2023
• 7.4. Participant's Overview
  • 7.4.1. Medtronic
    • 7.4.1.1. Overview
    • 7.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 7.4.1.3. Product Benchmarking
    • 7.4.1.4. Strategic Initiatives
  • 7.4.2. Evonik Industries AG
    • 7.4.2.1. Overview
    • 7.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 7.4.2.3. Product Benchmarking
    • 7.4.2.4. Strategic Initiatives
  • 7.4.3. Carpenter Technology Corporation
    • 7.4.3.1. Overview
    • 7.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 7.4.3.3. Product Benchmarking
    • 7.4.3.4. Strategic Initiatives
  • 7.4.4. Berkeley Advanced Biomaterials
    • 7.4.4.1. Overview
    • 7.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 7.4.4.3. Product Benchmarking
    • 7.4.4.4. Strategic Initiatives
  • 7.4.5. Invibio Ltd
    • 7.4.5.1. Overview
    • 7.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 7.4.5.3. Product Benchmarking
    • 7.4.5.4. Strategic Initiatives
  • 7.4.6. Zimmer Biomet Holdings, Inc
    • 7.4.6.1. Overview
    • 7.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 7.4.6.3. Product Benchmarking
    • 7.4.6.4. Strategic Initiatives
  • 7.4.7. BASF SE
    • 7.4.7.1. Overview
    • 7.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 7.4.7.3. Product Benchmarking
    • 7.4.7.4. Strategic Initiatives
  • 7.4.8. Covalon Technologies Ltd
    • 7.4.8.1. Overview
    • 7.4.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 7.4.8.3. Product Benchmarking
    • 7.4.8.4. Strategic Initiatives
  • 7.4.9. Stryker
    • 7.4.9.1. Overview
    • 7.4.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 7.4.9.3. Product Benchmarking
    • 7.4.9.4. Strategic Initiatives
  • 7.4.10. Johnson & Johnson
    • 7.4.10.1. Overview
    • 7.4.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 7.4.10.3. Product Benchmarking
    • 7.4.10.4. Strategic Initiatives
  • 7.4.11. Dentsply Sirona
    • 7.4.11.1. Overview
    • 7.4.11.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 7.4.11.3. Product Benchmarking
    • 7.4.11.4. Strategic Initiatives
  • 7.4.12. CoorsTek Inc
    • 7.4.12.1. Overview
    • 7.4.12.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 7.4.12.3. Product Benchmarking
    • 7.4.12.4. Strategic Initiatives
  • 7.4.13. Corbion
    • 7.4.13.1. Overview
    • 7.4.13.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 7.4.13.3. Product Benchmarking
    • 7.4.13.4. Strategic Initiatives
  • 7.4.14. Regenity Biosciences
    • 7.4.14.1. Overview
    • 7.4.14.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 7.4.14.3. Product Benchmarking
    • 7.4.14.4. Strategic Initiatives

관련자료